Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy.

Clinical work with radiolabeled anti-tumor antibodies has made remarkable progress in the past few years. Still, there is much to be done before these new reagents can have a substantial impact on the practical management of patients. In this discussion, the properties of an "ideal" radiolabeled antibody and important factors for in vivo localization in tumors are reviewed. Potential approaches to improving the localization of currently available "tumor specific" monoclonal antibodies are discussed and examples of patients examined and treated with this method are presented. Experience to date suggests that within the foreseeable future, radiolabeled antibody techniques will become a "genuinely decisive technology".

[1]  V. Diehl,et al.  Nuclear Oncology: Current Role and Future Direction , 1986 .

[2]  I. East,et al.  Scintigraphy of normal mouse ovaries with monoclonal antibodies to ZP-2, the major zona pellucida protein. , 1984, Science.

[3]  S. Larson,et al.  Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. , 1985, Radiology.

[4]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[5]  J. Brown,et al.  Studies of a high molecular weight human melanoma-associated antigen. , 1983, Journal of immunology.

[6]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Kim,et al.  Imaging approach in radioimmunodetection. , 1980, Cancer research.

[8]  I. Royston,et al.  Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. , 1980, Journal of immunology.

[9]  S. Larson,et al.  Nuclear oncology 1984. , 1984, Seminars in nuclear medicine.

[10]  S. Larson,et al.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.

[11]  S. Larson,et al.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. , 1984, Cancer treatment reports.

[12]  A. Brink.  A Dry White Season , 1979 .

[13]  S. Larson,et al.  Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  S. Larson,et al.  Imaging of melanoma with L-131-labeled monoclonal antibodies. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[16]  S. Larson,et al.  Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies. , 1983, JAMA.

[17]  R. Doolittle,et al.  Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.

[18]  S. Larson,et al.  High-level iodination of monoclonal antibody fragments for radiotherapy. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  S. Larson,et al.  IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODY , 1984, The Lancet.